INVESTOR ALERT: Class Action Lawsuit Against EDAP TMS S.A. Filed By Glancy Binkow & Goldberg LLP

Glancy Binkow & Goldberg LLP, representing investors of EDAP TMS S.A. (“EDAP” or the “Company”) (NASDAQ:EDAP), has filed a class action lawsuit in the United States District Court for the Southern District of New York on behalf of a class (the “Class”) comprising purchasers of the Company’s securities between February 1, 2013 and July 30, 2014, inclusive (the "Class Period").

Please contact Casey Sadler at (310) 201-9150, or at shareholders@glancylaw.com to discuss this matter. If you inquire by email, please include your mailing address, telephone number and number of shares purchased.

EDAP, through its subsidiaries, develops, produces and markets minimally invasive medical devices for the treatment of urological diseases. The Company offers the Ablatherm-HIFU device for the treatment of organ-confined prostate cancer. The Complaint alleges that defendants made false and/or misleading statements and/or failed to disclose that: (i) the Company overstated the efficacy and safety of its Ablatherm trials by relying on cross-study comparisons rather than a head-to-head trial; (ii) the study’s survival endpoint was inappropriate for the patient population; and (iii) as a result of the above, the Company's statements about its business and operations were materially false and misleading at all relevant times.

On July 30, 2014, the FDA announced that the panel convened to review EDAP’s Ablatherm-HIFU submission unanimously found that EDAP had failed to demonstrate the efficacy of its product or that it had demonstrated that the benefits of the device outweighed its risk. Following this news, shares of EDAP declined more than 40 percent on July 31, 2014.

If you are a member of the Class described above, you may move the Court no later than October 3, 2014, to serve as lead plaintiff, if you meet certain legal requirements. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Casey Sadler, Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century Park East, Suite 2100, Los Angeles, California 90067, at (310) 201-9150, by e-mail to shareholders@glancylaw.com, or visit our website at http://www.glancylaw.com. If you inquire by email, please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.